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Abstract
Islet amyloid polypeptide (IAPP or amylin) forms amyloid deposits in the islets of Langerhans; a process that is believed to
contribute to the progression of type 2 diabetes and to the failure of islet transplants. An emerging theme in amyloid
research is the hypothesis that the toxic species produced during amyloid formation by different polypeptides share
common features and exert their effects by common mechanisms. If correct, this suggests that inhibitors of amyloid
formation by one polypeptide might be effective against other amyloidogenic sequences. IAPP and Ab, the peptide
responsible for amyloid formation in Alzheimer’s disease, are particularly interesting in this regard as they are both natively
unfolded in their monomeric states and share some common characteristics. Comparatively little effort has been expended
on the design of IAPP amyloid inhibitors, thus it is natural to inquire if Ab inhibitors are effective against IAPP, especially
since no IAPP inhibitors have been clinically approved. A range of compounds inhibit Ab amyloid formation, including
various stereoisomers of inositol. Myo-, scyllo-, and epi-inositol have been shown to induce conformational changes in Ab
and prevent Ab amyloid fibril formation by stabilizing non-fibrillar b-sheet structures. We investigate the ability of inositol
stereoisomers to inhibit amyloid formation by IAPP. The compounds do not induce a conformational change in IAPP and are
ineffective inhibitors of IAPP amyloid formation, although some do lead to modest apparent changes in IAPP amyloid fibril
morphology. Thus not all classes of Ab inhibitors are effective against IAPP. This work provides a basis of comparison to
work on polyphenol based inhibitors of IAPP amyloid formation and helps provide clues as to the features which render
them effective. The study also helps provide information for further efforts in rational inhibitor design.
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Introduction
Amyloid formation plays a role in a broad range of human
diseases including Alzheimer’s disease, Parkinson’s disease and
type 2 diabetes (T2D) [1,2]. Islet amyloid polypeptide (IAPP or
amylin) is a neuroendocrine hormone that forms amyloid deposits
in the pancreatic islets of Langerhans in T2D [3,4]. The peptide
normally suppresses postprandial glucagon secretion, helps regu-
late gastric emptying, and induces satiety, thereby complementing
the effects of insulin in glycemic control, but IAPP forms islet
amyloid in T2D by an unknown mechanism [5–8]. Islet amyloid
formation is associated with the reduction of b cell mass in T2D
and is believed to contribute to the progression of the disease [9–
11]. Recent investigations have revealed that islet amyloid
contributes to graft failure after islet transplantation [12,13]. IAPP
is produced as a prohormone, and is processed in the Golgi and in
the insulin secretory granule, where it is stored. Mature IAPP is 37
residues in length with a disulfide bond between Cys-2 and Cys-7
and an amidated C-terminus (Figure 1). The peptide aggregates
aggressively in vitro and is toxic to cultured pancreatic islet b cells
and islets [14].
An emerging theme in amyloid research is the hypothesis that
the toxic species produced during amyloid formation share
common physio-chemical features and exert their deleterious
effects by common modes [15–19]. If correct, this suggests that
inhibitors of amyloid formation by one polypeptide might be
effective against other amyloidogenic sequences. IAPP and Ab are
particularly interesting in this regard as both are natively unfolded
in their monomeric states, and although they have modest
sequence identity, they do share some common characteristics
(Figure 1) [20]. The two polypeptides are similar in length, 37
versus 40 or 42 residues, are both ‘‘natively unfolded’’, and both
contain conserved aromatic residues. Comparatively little effort
has been expended on the design and development of islet amyloid
inhibitors compared to that invested in studies of Ab inhibitors.
Thus, it is natural to inquire if Ab inhibitors are effective against
IAPP in light of the features shared by the two polypeptides, and
given that amyloid formation by IAPP can be seeded by Ab [20].
None of the existing IAPP inhibitors have been clinically approved
and the mechanism of their action is not well understood. Thus,
new classes of IAPP amyloid inhibitors are required [21–28].
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Several peptide inhibitors, based on the full sequence of IAPP,
have been derived that are effective against Ab in vitro [22,25,29].
The polyphenol epigallocatechin-3-gallate (EGCG) inhibits amy-
loid formation by a wide range of natively unfolded polypeptides
including Ab and IAPP, but its mode of action is not clear, and in
some cases might involve chemical modification of the target
peptide [27,30–32]. Another polyphenol, resveratrol, has also
been reported to inhibit in vitro amyloid formation by IAPP and
Ab [33,34]. However, neither polyphenols nor the peptide based
inhibitors are ‘‘drug like’’ and it is not clear if the results with these
compounds are generalizable.
A range of compounds, in addition to polyphenols, have been
reported to inhibit Ab amyloid formation, including various
stereoisomers of inositol, but have not been tested against IAPP.
Inositols are a class of cyclohexylpolyols with eight naturally
occurring stereoisomers, the physiologically active four of which
are: myo-, chiro-, epi- and scyllo-inositol (Figure 1) [35]. Both
myo- and scyllo-inositol are found in the human central nervous
system, and myo-inositol, the most abundant stereoisomer, is the
head group of phosphotidylinositol and plays a role in a range of
physiological processes [35,36]. In vitro studies have shown that
inositol stereoisomers inhibit amyloid formation by Ab42 in a
stereochemistry-dependent manner. Myo-, scyllo-, and epi-inositol
induce conformational changes in Ab, and prevent Ab amyloid
fibril formation by stabilizing non-fibrillar, b-sheet structures, and
have been shown to protect cultured neuronal cells from Ab-
induced toxicity, while chiro-inositol does not have these effects
[37,38]. These studies were conducted with the inositol stereoiso-
mers in large excess, at a peptide to inositol ratio of 1 to 20 by
weight (,1 to 500 by molar). A more recent study of the
interaction of Ab42 and scyllo-inositol used thioflavin-T fluores-
cence assays to show that the compound, when added in a 10-fold
molar excess, only slightly slowed the rate of Ab42 amyloid
formation, but did not abolish fibril formation [39]. The two
studies argue that the capability of inositol to inhibit Ab42 amyloid
formation is dose dependent. This conclusion is supported by a
recent ion mobility spectrometry study conducted at a peptide to
scyllo-inositol ratio of 1 to 1, which revealed that scyllo-inositol
reduced the extent of oligomer formation by a fragment of Ab,
Ab(25–35), but did not prevent the formation of oligomers with b-
sheet fibrillar structure [40]. Collectively, the in vitro data indicate
that scyllo-inositol inhibits Ab amyloid formation in a dose
dependent manner and protects cultured neurons. Scyllo-inositol
has also been reported to prevent and reverse the Alzheimer
phenotype in a mouse model [41].
This class of compounds has not been investigated as IAPP
inhibitors and the most effective small molecule anti-IAPP
compounds in vitro, polyphenols and sulfated triphenyl methyl
compounds, are undesirable as drug leads. Thus, it is important to
expand the chemical diversity of potential IAPP inhibitors. Given
the similarities between IAPP and Ab, and the fact that a number
of compounds have been shown to be active against both
molecules, it is reasonable to examine the effects of different
classes of Ab inhibitors on IAPP. Here we investigate the activity
of four inositol stereoisomers to inhibit amyloid formation by
IAPP. The compounds do not induce a conformational change in
soluble IAPP and are ineffective inhibitors of IAPP amyloid
formation, although some do lead to modest changes in IAPP
amyloid fibril morphology. Thus not all classes of Ab inhibitors are
effective against IAPP.
The study is also of interest as a basis of comparison to work on
polyphenol based inhibitors of IAPP amyloid formation. EGCG,
resveratrol, and other polyphenols inhibit IAPP amyloid forma-
tion, but the mechanism is not fully understood [26,27,33,42].
EGCG is believed to function by diverting IAPP into non-
productive, ‘‘off-pathway’’ aggregates that are not competent to go
Figure 1. Peptide sequences and inositol structures. (A) Sequence of IAPP and Ab42. The molecules are aligned according to reference 20.
Residues which are identical in both sequences are labeled in red. IAPP has a disulfide bond between Cys 2 and Cys 7 and an amidated C-terminus.
(B) Structures of the inositol stereoisomers examined in this work.
doi:10.1371/journal.pone.0104023.g001
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on to form amyloid [30,31,42]. However, the molecular structures
of these aggregates are not known. It is not known if the effects are
due to their multiple hydroxyl functionalities, their polyphenolic
character, their ability, in some cases, to covalently modify
proteins, or other features [26–28,32,42]. The inositols are not
aromatic, but are rich in hydroxyl groups that can potentially
hydrogen-bond to IAPP, particularly as IAPP has a large number
of residues with side chains that contain hydrogen-bond donors
and acceptors (Figure 1). The results help provide clues about the
features important in polyol and polyphenol based IAPP amyloid
inhibitors and may help provide a basis for further rational
inhibitor design.
Materials and Methods
Peptide Synthesis
IAPP was synthesized using a CEM microwave peptide
synthesizer on a 0.1 mmol scale, utilizing 9-fluorenylmethylox-
ycarbonyl (Fmoc) chemistry. 5-(49-Fmoc-aminomethyl-395-di-
methoxyphenol) valeric acid (PAL-PEG) resin was used in order
to afford an amidated C-terminus. To improve the yield, Fmoc-
protected pseudoproline (oxazolidine) dipeptide derivatives were
incorporated as previously described [43]. Standard Fmoc
reaction cycles were used as previously described [44]. The first
residue attached to the resin, all b-branched residues and all
pseudoproline dipeptide derivatives were double-coupled. Stan-
dard trifluoroacetic acid (TFA) methods were employed to cleave
the peptides from the resin.
Peptide Oxidation and Purification
After cleavage, crude peptides were dissolved into 20% (v/v)
acetic acid and then lyophilized. This step was repeated several
times before oxidation to improve the solubility of the peptides.
The dry peptides were dissolved into 100% dimethyl sulfoxide at
room temperature to promote disulfide formation and were
purified via reverse-phase high-performance liquid chromatogra-
phy using a Vydac C18 preparative column [45]. The purity of the
peptide was checked by analytical HPLC before each experiment,
and the mass of the peptide was identified by ionization time-of-
flight mass spectrometry; IAPP, expected 3903.6, observed 3904.6.
Sample Preparation
Myo-, scyllo-, and chiro-inositol were purchased from Sigma.
Epi-inositol was purchased from TCI America. They were used
without further purification. Compounds were dissolved in
20 mM Tris-HCl buffer at pH 7.4 to make 50 mM stock solutions
before each experiment. IAPP was dissolved in 100% hexafluor-
oisopropanol (HFIP) to make a 1.6 mM stock solution. Stock
solutions of the peptide were filtered using 0.45 mM Acrodisc
syringe filter with a GHP membrane and the required amount of
peptide was lyophilized overnight to remove HFIP. Dry peptide
was dissolved into Tris-HCl buffer for the fluorescence experi-
ments.
Thioflavin-T Detected Fluorescence Assays
Amyloid formation was monitored by thioflavin-T binding
assays conducted without stirring at 25uC. A Beckman Coulter
DTX 880 plate reader with a multimode detector was used to
measure the fluorescence, using an excitation wavelength of
430 nm and an emission wavelength of 485 nm. Immediately
before the measurement, dry peptide was dissolved into Tris-HCl
buffer and thioflavin-T solution, followed by the addition of
inositol from stock solutions when inositol was used. The final
concentrations were 16 mM IAPP and 32 mM thioflavin-T in
20 mM Tris-HCl (pH 7.4) When inositol was present, the IAPP to
inositol ratio was at 1 to 20 by weight. Experiments were repeated
three times and reported time constants are average 6 standard
deviation.
Circular Dichroism (CD)
Far-UV CD experiments were performed on an Applied
Photophysics Chirascan CD spectrophotometer at 25uC. Aliquots
from the kinetic experiments were removed at the time points of
interest and the spectra were recorded as the average of three
repeats over a range of 190–260 nm, at 1 nm intervals. A 0.1 cm
quartz cuvette was used and a background spectrum was
subtracted from each measurement.
Transmission Electron Microscopy (TEM)
TEM images were collected at the Life Science Microscopy
Center at Stony Brook University. 15 mL aliquots were removed
from the solution, blotted on a carbon-coated 200-mesh copper
Figure 2. Inositols do not induce a conformational change in IAPP. CD spectra of IAPP in the presence of different inositol stereoisomers at
the beginning of the amyloid formation reaction (A) and after 300 min incubation (B). Black, IAPP; red, IAPP + myo-inositol; green, IAPP + epi-inositol;
purple, IAPP + scyllo-inositol; blue, IAPP + chiro-inositol. The concentration of IAPP was 16 mM. The IAPP to inositol ratio was 1 to 20 by weight in each
mixture. The experiments were conducted in 20 mM Tris-HCl (pH 7.4), without stirring at 25uC.
doi:10.1371/journal.pone.0104023.g002
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grid for 1 min and then negatively stained with saturated uranyl
acetate for 1 min.
Results and Discussion
Inositols do not induce a conformational change in IAPP,
unlike their effect on Ab
Previous studies have shown that myo-, epi- and scyllo-inositol
rapidly induce Ab42 to form b-structure, while chiro-inositol does
not [37,38]. To test if inositol exerts similar effects on IAPP, we
incubated the polypeptide with each stereoisomer separately at a
peptide to inositol ratio of 1 to 20 by weight, chosen to mimic the
conditions used for the Ab studies. CD was used to monitor the
conformation of IAPP. Immediately after mixing, all of the
samples showed typical random coil structure CD spectra which
were indistinguishable from the spectrum of IAPP alone (Figure 2),
indicating that the compounds exert different effects on IAPP
compared to Ab. TEM images of all of the mixtures were similar
to images recorded of freshly dissolved IAPP alone and revealed
only a few amorphous aggregates (Figure 3). Under the conditions
of our experiments, IAPP forms amyloid with a lag time of about
10 hours. We collected the CD spectra again after 5 hours
incubation, a time chosen to be in the middle of the lag phase, but
did not observe any obvious conformational change induced by
any of the four inositol stereoisomers (Figure 2).
Inositol is a modest inhibitor of IAPP aggregation, but
does not abolish amyloid fibril formation
In the case of Ab42, three of the isomers proved to be effective
at inhibiting amyloid formation. No fibrils were detected during
the time course of the experiments conducted in the presence of
myo-, epi-, and scyllo-inositol, but fibrils with typical Ab42
amyloid fibril morphology were observed in the presence of chiro-
inositol. We measured the kinetics of amyloid formation by IAPP
in the presence of each inositol stereoisomer using fluorescence
detected thioflavin-T binding assays. Thioflavin-T is a small dye
that undergoes an increase in its quantum yield upon binding to
amyloid fibrils and is widely used to monitor the kinetics of
amyloid formation. Prior work has shown that the dye does not
perturb the kinetics of IAPP amyloid formation under the
conditions used here. As shown in Figure 4, the four stereoisomers
have modest inhibitory effects on IAPP amyloid formation. Myo-
inositol, the most potent inhibitor among the four against IAPP
was still only weakly effective, and increased the lag phase of IAPP
amyloid formation by a factor of 2.060.13, compared to a factor
of 1.560.10 for epi-inositol and 1.360.06 for scyllo-inositol. These
are small effects, but they are reproducible. Comparison to the
published data on inositol Ab interactions shows that the
compounds are far less effective at inhibiting IAPP amyloid
formation [37,38]. The fourth stereoisomer, chiro-inositol, barely
changed the lag time of IAPP in our studies with a T50 only 10%
longer than in the absence of the compound. The result with
chiro-inositol is generally consistent with the results of the earlier
work on Ab. We collected TEM images at the end of each reaction
to examine the effects of the different inositol stereoisomers on
fibril morphology. The fibrils formed by IAPP in the presence of
chiro- or epi-inositol had a morphology that was indistinguishable
from that observed for fibrils formed by IAPP alone. In contrast, in
the presence of myo- or scyllo-inositol, shorter fibrils were
observed (Figure 5). There is no obvious direct correlation
between the effects on the lag phase and the effects of the
compounds on fibril morphology. This is not surprising given that
only small effects are observed on both.
The potential molecular basis for the different effects of
inositols on Ab and IAPP
The mechanism of inositol-Ab42 interaction is not fully
understood. Molecular dynamics (MD) simulations have led to
the hypothesis that scyllo- and chiro-inositol exhibit similar weak
binding to a seven residue core fragment of Ab, Ab (16–22), which
contains a di-phenylalanine sequence. This work suggested that a
stereospecific face-to-face stacking mode of scyllo-inositol with the
Figure 3. TEM images at the beginning of the amyloid formation reaction. (A) IAPP (B) IAPP + myo-inositol (C) IAPP + epi-inositol (D) IAPP +
scyllo-inositol (E) IAPP + chiro-inositol. Scale bars represent 100 nm. The concentration of IAPP was 16 mM. The IAPP to inositol ratio was 1 to 20 by
weight in each mixture. The experiments were conducted in 20 mM Tris-HCl (pH 7.4), without stirring at 25uC.
doi:10.1371/journal.pone.0104023.g003
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Phe side chains in Ab plays a role in the ability of the compound to
inhibit amyloid formation. The stacking is postulated to result
from the interaction of the two hydrophobic planar surfaces in the
compound with Ab. The equatorial position of the hydroxyls in
scyllo-inositol leads to two hydrophobic faces, and this, combined
with a higher propensity for hydrogen bonding, was proposed to
contribute to the observed stereochemistry-dependent activity
[46,47]. The simulations also suggested that inositol inhibits Ab
amyloid formation by preventing the lateral association or stacking
of protofibrillar b-sheet oligomers [47]. IAPP contains three
aromatic residues, F15, F23 and Y37, but lacks a di-aromatic
sequence. The prior results, together with a sequence comparison
of IAPP and Ab, suggest that inositol peptide interactions are
sequence specific and may depend on the aromatic sequence in
Ab. An alternative explanation, that we cannot rule out, is that the
aggregation pathways of the two peptides might be different and
inositols may more effectively target the Ab pathway.
Conclusions
We have characterized the ability of myo-, scyllo-, epi- and
chiro-inositol to inhibit amyloid formation by IAPP. Their efficacy
is stereo-chemically dependent. Chiro-inositol does not affect IAPP
amyloid formation, consistent with prior studies on Ab. However,
the remaining three inositol stereoisomers clearly have much less
effect upon IAPP amyloid formation than they do on Ab amyloid
formation. Myo-inositol, the most potent inhibitor among the four
under our experimental conditions, still had only very modest
effects and increased the lag time of IAPP amyloid formation by
just 2 fold. In sharp contrast, according to published reports, myo-,
epi-, and scyllo-inositol totally abolish amyloid fibril formation by
Ab when added at the same concentration used here [37,38].
Moreover, these inositol stereoisomers stabilized non-fibrillar b-
structure in Ab, an effect that was proposed to contribute to the
inhibition of fibril formation [37,38]. In contrast, none of the
stereoisomers tested were capable of inducing an initial confor-
mational change in IAPP, similar to that seen for Ab. These
observations clearly indicate that the design of amyloid inhibitors
is likely to be specific for the protein of interest, and show that,
while some compounds can inhibit multiple amyloidogenic
proteins, not all inhibitors of one protein will be effective against
a similar amyloidogenic peptide.
Myo- and scyllo-inositol did have a modest effect on IAPP fibril
morphology and shorter fibrils were observed in their presence.
The effects of the inositol stereoisomers on fibril morphology are
small, but are dependent on the spatial distribution of the hydroxyl
groups. IAPP contains a large fraction of residues with hydrogen
bonding functionalities in their side chains (Figure 1), including
ten Thr or Ser residues and seven Asn or Gln residues, and these
provide multiple potential sites for hydrogen bonding interactions
with the inositols.
Certain polyphenols have been proven to be potent in vitro
inhibitors of amyloid formation by IAPP and Ab. EGCG is
particularly effective and abolishes IAPP amyloid formation when
added at a 1 to 1 molar ratio [26]. Resveratrol is less effective, but
does inhibit amyloid formation by both peptides. It is not clear if
the effects are due to the multiple hydroxyl groups of EGCG, its
polyphenolic character, or its susceptibility to spontaneous
modifications [32]. The fact that the inhibitory ability of inositol
stereoisomers are stereochemistry-dependent, and are much less
effective on IAPP amyloid formation than EGCG or resveratrol,
indicates that factors other than simply multiple hydroxyl groups
are important for polyphenol IAPP interactions [26,27]. These
likely include the aromatic character of the polyphenols, the larger
hydrophobic surfaces presented by EGCG, and the distribution of
the hydroxyl groups. Along these lines, the polyhydroxyl groups on
the planar aromatic rings of EGCG have a very different spatial
arrangement than those in the inositols and prior work has
suggested that the distribution of the hydroxyls in polyphenols
influences their ability to inhibit IAPP amyloid formation [27,28].
In the case of EGCG, its ability to form covalent linkages with
polypeptides may also contribute. The sequence targets of
resveratrol and EGCG are not known, although EGCG has been
proposed to interact with the peptide backbone and to make
relatively non-specific interactions with sidechains [27,31]. This
may account, in part, for the lack of specificity of EGCG. Studies
with IAPP analogs have revealed that aromatic residues are not
important for IAPP EGCG interactions, while the computational
studies summarized above have suggested that di-aromatic
sequences could be important for inositol peptide interactions.
This too might contribute to the different specificity of EGCG
versus inositols.
Figure 4. The effect of inositols on IAPP amyloid formation
depends on their stereochemistry. (A) Kinetic curves of amyloid
formation by IAPP and mixtures of IAPP with inositol stereoisomers as
monitored by thioflavin-T fluorescence assays. Black, IAPP; red, IAPP +
myo-inositol; green, IAPP + epi-inositol; purple, IAPP + scyllo-inositol;
blue, IAPP + chiro-inositol. (B) A bar graph comparing the effects of the
different inositols on the value of T50. Data is plotted as T50 normalized
by the T50 of IAPP in the absence of any compounds. Error bars
represent standard deviations for three repeats. The concentration of
IAPP was 16 mM. The IAPP to inositol ratio was 1 to 20 by weight in each
mixture. The experiments were conducted in 20 mM Tris-HCl (pH 7.4),
without stirring at 25uC.
doi:10.1371/journal.pone.0104023.g004
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